Pfizer recently announced the results of its Phase 2 clinical trial of lorlatinib, a next-generation tyrosine kinase inhibitor to treat patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), in fighting lung tumors and brain metastases.
Pfizer Inc. said it prepared 10 abstracts on Xeljanz (tofacitinib) in treating ulcerative colitis (UC) for presentation at the World Congress of Gastroenterology at the American College of Gastroenterology in Florida and the 25th United European Gastroenterology (UEG) in Spain.
Merck KGaA and Pfizer Inc. recently obtained approval of Bavencio (avelumab) as Japan’s first treatment for Merkel cell carcinoma (MCC), citing endorsement from the Japanese Ministry of Health, Labor and Welfare (MHLW).
According to a recent study, over 75 percent of those age 65 and older are not screened for atrial fibrillation (AF) and similar stroke risk markers during primary care exams despite that demographic being prone to stroke, a Bristol-Myers Squibb release said.
Positive results from a Phase 3 clinical trial recently prompted the European Commission to approve Besponsa, Pfizer Inc.’s new immunotherapy treatment for patients suffering from B-cell precursor acute lymphoblastic leukemia, the pharmaceutical said in a release.
Pfizer said its drug tafamidis, an investigational treatment for transthyretin cardiomyopathy (TTR-CM), a rare, fata disease linked to progressive heart failure, has been granted U.S. Food and Drug Administration (FDA) fast track designation.
In a move that could help open the U.S. market for biosimilars, a U.S. Food and Drug Administration subcommittee recently greenlighted Pfizer Inc.’s epoetin alfa compound, an emulation of two medicines designed to relieve anemia in patients who have cancer and kidney disease.
An amendment to an international Phase 3 clinical trial for prostate cancer drug Xtandi (enzalutamide) will cut the sample size by 120 subjects and provide results later this year, nearly two years ahead of schedule.
Pfizer said in a release that it has enhanced its stable of oncology therapies with the March 31 announcement that the FDA has expanded the drugmaker's Ibrance medication for treatment of metastatic breast cancer in post-menopausal women.